News Releases

Date Title  
Toggle Summary Adamis Pharmaceuticals Announces Presentation of ZIMHI data at IHV Scientific Meeting
SAN DIEGO , Oct. 08, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the presentation of data pertaining to its investigational high dose naloxone product (ZIMHI) at the Institute of Human Virology (IHV) meeting (
Adamis Pharmaceuticals Announces Presentation of ZIMHI data at IHV Scientific Meeting
SAN DIEGO , Oct. 08, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the presentation of data pertaining to its investigational high dose naloxone product (ZIMHI) at the Institute of Human Virology (IHV) meeting (
Toggle Summary Adamis Pharmaceuticals Announces Commercial Partnership with Emerge Health for SYMJEPI® in Australia and New Zealand
SAN DIEGO , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that it has entered into an exclusive distribution and commercialization agreement with Emerge Health Pty (“Emerge”) to register and commercialize Adamis’ SYMJEPI ® (epinephrine)
Adamis Pharmaceuticals Announces Commercial Partnership with Emerge Health for SYMJEPI® in Australia and New Zealand
SAN DIEGO , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that it has entered into an exclusive distribution and commercialization agreement with Emerge Health Pty (“Emerge”) to register and commercialize Adamis’ SYMJEPI ® (epinephrine)
Toggle Summary Adamis Pharmaceuticals Announces Presentation Pertaining to Its High Dose Naloxone Product Candidate at IHV Scientific Meeting
SAN DIEGO , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that Dr. Ronald Moss , Chief Medical Officer, will be presenting data on October 4, 2019 , pertaining to the company’s investigational high dose naloxone product candidate (ZIMHI) at the
Adamis Pharmaceuticals Announces Presentation Pertaining to Its High Dose Naloxone Product Candidate at IHV Scientific Meeting
SAN DIEGO , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that Dr. Ronald Moss , Chief Medical Officer, will be presenting data on October 4, 2019 , pertaining to the company’s investigational high dose naloxone product candidate (ZIMHI) at the
Toggle Summary Adamis Pharmaceuticals Provides Update for Naloxone Product Candidate
SAN DIEGO , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today the completion of pharmacokinetic (PK) studies comparing its naloxone injection product candidate, ZIMHI TM (naloxone) Injection, to a generic naloxone comparator.
Adamis Pharmaceuticals Provides Update for Naloxone Product Candidate
SAN DIEGO , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today the completion of pharmacokinetic (PK) studies comparing its naloxone injection product candidate, ZIMHI TM (naloxone) Injection, to a generic naloxone comparator.
Toggle Summary Adamis Pharmaceuticals Provides Launch and Marketing Update for SYMJEPI
SAN DIEGO , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a progress report and marketing update on the U.S. launch of SYMJEPI TM  (epinephrine) 0.3 mg and 0.15 mg Injections. During this back-to-school season, there is a heightened awareness of
Adamis Pharmaceuticals Provides Launch and Marketing Update for SYMJEPI
SAN DIEGO , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a progress report and marketing update on the U.S. launch of SYMJEPI TM  (epinephrine) 0.3 mg and 0.15 mg Injections. During this back-to-school season, there is a heightened awareness of
Toggle Summary Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors
SAN DIEGO , Aug. 26, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the appointment of Howard C. Birndorf and Roshawn Blunt to its Board of Directors. Dr. Dennis J. Carlo , President and CEO of Adamis, stated, “We are very excited to bring on these two
Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors
SAN DIEGO , Aug. 26, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the appointment of Howard C. Birndorf and Roshawn Blunt to its Board of Directors. Dr. Dennis J. Carlo , President and CEO of Adamis, stated, “We are very excited to bring on these two
Toggle Summary Adamis Pharmaceuticals Strengthens Patent Portfolio for its U.S. Compounding Subsidiary
SAN DIEGO , Aug. 14, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application (U.S. Patent Application No.
Adamis Pharmaceuticals Strengthens Patent Portfolio for its U.S. Compounding Subsidiary
SAN DIEGO , Aug. 14, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application (U.S. Patent Application No.
Toggle Summary Adamis Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update
SAN DIEGO , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2019 and provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals ,
Adamis Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update
SAN DIEGO , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2019 and provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals ,
Toggle Summary Adamis Pharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call and Business Update
SAN DIEGO , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”), a specialty biopharmaceutical company primarily focused on developing and commercializing products in the therapeutic areas of allergy, respiratory disease and opioid overdose, announced
Adamis Pharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call and Business Update
SAN DIEGO , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”), a specialty biopharmaceutical company primarily focused on developing and commercializing products in the therapeutic areas of allergy, respiratory disease and opioid overdose, announced
Toggle Summary Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants
SAN DIEGO , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy and opioid overdose, announced today the
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants
SAN DIEGO , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy and opioid overdose, announced today the
Toggle Summary Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
SAN DIEGO , July 31, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy and opioid overdose, announced today that it
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
SAN DIEGO , July 31, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy and opioid overdose, announced today that it
Toggle Summary Adamis Pharmaceuticals Provides Update on Litigation with Belcher Pharmaceuticals
SAN DIEGO , July 24, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that Adamis and Belcher Pharmaceuticals, LLC (“Belcher”) agreed to settle all previously filed litigation between the parties, including the case filed by Adamis in the United
Adamis Pharmaceuticals Provides Update on Litigation with Belcher Pharmaceuticals
SAN DIEGO , July 24, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that Adamis and Belcher Pharmaceuticals, LLC (“Belcher”) agreed to settle all previously filed litigation between the parties, including the case filed by Adamis in the United
Toggle Summary Adamis Pharmaceuticals Provides Update on Litigation with kaléo Inc.
SAN DIEGO , July 18, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that Adamis and kaléo Inc. agreed to settle all previously announced litigation between the parties, including the case filed by kaléo in the United States District Court for
Adamis Pharmaceuticals Provides Update on Litigation with kaléo Inc.
SAN DIEGO , July 18, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that Adamis and kaléo Inc. agreed to settle all previously announced litigation between the parties, including the case filed by kaléo in the United States District Court for
Toggle Summary Adamis Pharmaceuticals Provides Update on U.S. Retail Launch of SYMJEPI
SAN DIEGO , July 09, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) provided an update that Sandoz Inc. ( Sandoz ), a Novartis division, today announced the U.S. retail launch of SYMJEPI™ (epinephrine) 0.3 mg and 0.15 mg Injections, making both the adult and pediatric
Adamis Pharmaceuticals Provides Update on U.S. Retail Launch of SYMJEPI
SAN DIEGO , July 09, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) provided an update that Sandoz Inc. ( Sandoz ), a Novartis division, today announced the U.S. retail launch of SYMJEPI™ (epinephrine) 0.3 mg and 0.15 mg Injections, making both the adult and pediatric
Toggle Summary Adamis Pharmaceuticals Provides Update on Litigation with kaléo Inc.
SAN DIEGO , June 27, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the litigation with kaléo Inc. regarding kaléo’s claims of patent infringement relating to Adamis’ higher dose naloxone injection product (ZIMHI TM ), as well as, new claims
Adamis Pharmaceuticals Provides Update on Litigation with kaléo Inc.
SAN DIEGO , June 27, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the litigation with kaléo Inc. regarding kaléo’s claims of patent infringement relating to Adamis’ higher dose naloxone injection product (ZIMHI TM ), as well as, new claims
Toggle Summary Adamis Pharmaceuticals Provides Update on Its Higher Dose Naloxone Injection Product
SAN DIEGO , June 11, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration ( FDA ) has acknowledged the receipt of Adamis’ amendment to its previously submitted New Drug Application (NDA) for its higher dose naloxone
Adamis Pharmaceuticals Provides Update on Its Higher Dose Naloxone Injection Product
SAN DIEGO , June 11, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration ( FDA ) has acknowledged the receipt of Adamis’ amendment to its previously submitted New Drug Application (NDA) for its higher dose naloxone
Toggle Summary Adamis Pharmaceuticals to Present at Conferences in June 2019
SAN DIEGO , May 29, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that management is scheduled to present a company overview at two upcoming conferences in June 2019.  During the conferences, management from Adamis will discuss the company’s business,
Adamis Pharmaceuticals to Present at Conferences in June 2019
SAN DIEGO , May 29, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that management is scheduled to present a company overview at two upcoming conferences in June 2019.  During the conferences, management from Adamis will discuss the company’s business,
Toggle Summary Adamis Pharmaceuticals Announces Patent Litigation Regarding Its Higher Dose Naloxone Injection Product
SAN DIEGO , May 21, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that on May 20, 2019 , it received notice that it had been named and served as a defendant in a lawsuit filed by kaléo Inc. in the United States District Court for the District of Delaware
Adamis Pharmaceuticals Announces Patent Litigation Regarding Its Higher Dose Naloxone Injection Product
SAN DIEGO , May 21, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that on May 20, 2019 , it received notice that it had been named and served as a defendant in a lawsuit filed by kaléo Inc. in the United States District Court for the District of Delaware
Toggle Summary Adamis Pharmaceuticals Announces Conditional Acceptance by FDA of Proprietary Name for Higher Dose Naloxone Product
SAN DIEGO , May 14, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today conditional acceptance by the U.S. Food and Drug Administration ( FDA ) of the proposed brand name for the company’s high dose naloxone product candidate.
Adamis Pharmaceuticals Announces Conditional Acceptance by FDA of Proprietary Name for Higher Dose Naloxone Product
SAN DIEGO , May 14, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today conditional acceptance by the U.S. Food and Drug Administration ( FDA ) of the proposed brand name for the company’s high dose naloxone product candidate.
Toggle Summary Adamis Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update
SAN DIEGO , May 09, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2019 and provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,
Adamis Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update
SAN DIEGO , May 09, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2019 and provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,
Toggle Summary Adamis Pharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update
SAN DIEGO , May 07, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas including respiratory disease and allergy, announced today that
Adamis Pharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update
SAN DIEGO , May 07, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas including respiratory disease and allergy, announced today that
Toggle Summary Adamis Pharmaceuticals Announces 2018 Financial Results and Provides Business Update
SAN DIEGO , March 15, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended December 31, 2018 and provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,
Adamis Pharmaceuticals Announces 2018 Financial Results and Provides Business Update
SAN DIEGO , March 15, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended December 31, 2018 and provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,
Toggle Summary Adamis Pharmaceuticals Announces FDA Acceptance for Review of the New Drug Application of Its Higher Dose Naloxone Injection Product Candidate
SAN DIEGO --(BUSINESS WIRE)--Mar. 14, 2019-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the company’s New Drug Application (“NDA”) for its higher naloxone injection product candidate for the treatment
Adamis Pharmaceuticals Announces FDA Acceptance for Review of the New Drug Application of Its Higher Dose Naloxone Injection Product Candidate
SAN DIEGO --(BUSINESS WIRE)--Mar. 14, 2019-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the company’s New Drug Application (“NDA”) for its higher naloxone injection product candidate for the treatment
Toggle Summary Adamis Provides Regulatory Update on Sublingual Tadalafil
SAN DIEGO , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received a Refusal to File letter from the United States Food and Drug Administration ( FDA ) regarding its New Drug Application (NDA) for its sublingual tadalafil product.
Adamis Provides Regulatory Update on Sublingual Tadalafil
SAN DIEGO , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received a Refusal to File letter from the United States Food and Drug Administration ( FDA ) regarding its New Drug Application (NDA) for its sublingual tadalafil product.
Toggle Summary Adamis Pharmaceuticals Publishes the Rationale for a Higher Dose Naloxone Product to Counter the Current Opioid Epidemic
SAN DIEGO , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that the article entitled “Higher doses of naloxone are needed in the synthetic opioid era” has been published in the peer reviewed journal Substance Abuse Treatment,
Adamis Pharmaceuticals Publishes the Rationale for a Higher Dose Naloxone Product to Counter the Current Opioid Epidemic
SAN DIEGO , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that the article entitled “Higher doses of naloxone are needed in the synthetic opioid era” has been published in the peer reviewed journal Substance Abuse Treatment,